Can a statin tame a cancer protein? early trial hints at possibility

This early-phase trial is testing whether atorvastatin, a widely used cholesterol medication, can reduce levels of a faulty protein called p53 in people with various cancers, including solid tumors and acute myeloid leukemia. About 50 participants will take the drug for 1 to 4 weeks before their planned surgery or treatment. The main goal is to measure changes in the mutant p53 protein, not to treat the cancer directly, so this study is focused on gathering knowledge rather than providing a cure.